الفهرس Only 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
Effective control of cancer related pain has long been one
of the most important and pressing issues with regard to oncology
and health (Arcidiacono and Rossi, 2004).
Pancreatic cancer commonly produces pain that is difficult
to control. Initial therapy with non steroidal anti-inflammatory
agents (NSAIDs) is often inadequate and necessitates opioid
administration which may impair immune function. Therefore,
non pharmacologic therapies, such as celiac plexus neurolysis
(CPN), are often given with the goal of improving pain control and
quality of life while reducing the risk of drug-related side effects
(Kaid et al, 2006).
Neurolytic celiac plexus block (NCPB) is an effective
method in the management of pain in patients suffering from upper
abdominal malignancies, such as pancreatic cancer, bile duct cancer
and primary liver neoplasm. It may be associated also with
prolonged survival (Panagiotiset al, 2006).
The success rate of the procedure for palliative relief of all
types of upper gastrointestinal cancer pain has been reported to be
between 70% and 97%, regardless of the technique used (Titton et
al, 2002).
Accordingly the celiac plexus transmits pain sensation
originating from the pancreas and most of the abdominal viscera
except for the left colon, rectum and pelvic organs. Celiac plexus
neurolysis (CPN) is a chemical splanchnicectomy of the celiac
plexus; its goal is to ablate the efferent nerve fibers which transmit.